Moderna Biopharma Canada Corporation

Meetings over time

• Jul 20251 meetingPierre Paul-Hus
  Jul 2025: 1 meeting, with Pierre Paul-Hus
• Aug 20252 meetingsManuela Tomic, David McFarlane, Ritu Banerjee
  Aug 2025: 2 meetings, with Manuela Tomic, David McFarlane, Ritu Banerjee
• Sep 20252 meetingsMarjorie Michel, Philip Jennings, Nancy Hamzawi, Ritu Banerjee, Andrea Gilpin
  Sep 2025: 2 meetings, with Marjorie Michel, Philip Jennings, Nancy Hamzawi, Ritu Banerjee, Andrea Gilpin
• Oct 20250 meetings
  Oct 2025: 0 meetings
• Nov 20252 meetingsMélanie Joly, Ritu Banerjee
  Nov 2025: 2 meetings, with Mélanie Joly, Ritu Banerjee
• Dec 20250 meetings
  Dec 2025: 0 meetings
• Jan 20260 meetings
  Jan 2026: 0 meetings
• Feb 20261 meetingDavid McFarlane, Manuela Tomic
  Feb 2026: 1 meeting, with David McFarlane, Manuela Tomic
• Mar 20260 meetings
  Mar 2026: 0 meetings
• Apr 20260 meetings
  Apr 2026: 0 meetings
• May 20260 meetings
  May 2026: 0 meetings
• Jun 20264 meetingsMarc-André Blanchard, Yash Nanda, Paul Moen, Manuela Tomic, Mackenzy Metcalfe
  Jun 2026: 4 meetings, with Marc-André Blanchard, Yash Nanda, Paul Moen, Manuela Tomic, Mackenzy Metcalfe
• Jul 20262 meetingsJade Mallette, Ann-Clara Vaillancourt, Loic Sénéchal
  Jul 2026: 2 meetings, with Jade Mallette, Ann-Clara Vaillancourt, Loic Sénéchal

Hover or focus a month to see who was met.

What they lobby about

• Science and Technology13
• Health12
• Research and Development7
• Economic Development6
• Government Procurement6
• Regional Development6

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

Innovation, Science and Economic Development Canada (ISED) (12) · Public Health Agency of Canada (PHAC) (6) · Health Canada (HC) (4) · Public Services and Procurement Canada (PSPC) (3) · Prime Minister's Office (PMO) (2) · Finance Canada (FIN) (1)

In their own words

• Communicating with government officials about procurement polices and procedures (including, but not limited to, those maintained by the Departments of Health and Public Services and Procurement), more specifically policies and procedures pertaining to the development, procurement and distribution of vaccines, including Moderna's messenger ribonucleic acid ("mRNA") vaccines.
• Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models
• Communicating with government officials, in general, about pharmaceutical and biotechnology policies, including those related to innovation, research and development and messenger ribonucleic acid ("mRNA") biotechnology.